

1 **Rafael Stroggilos^{1,3}, Maria Frantzi², Jerome Zoidakis¹, Emmanouil Mavrogeorgis^{1±}, Marika**
2 **Mokou², Maria G Roubelakis^{3,4}, Harald Mischak², Antonia Vlahou^{1*}**

3 1. Systems Biology Center, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

4 2. Mosaiques Diagnostics GmbH, Hannover, Germany.

5 3. Laboratory of Biology, National and Kapodistrian University of Athens, School of Medicine, Athens,
6 Greece

7 4. Cell and Gene Therapy Laboratory, Biomedical Research Foundation of the Academy of Athens, Athens,
8 Greece.

9 ±current address: Mosaiques Diagnostics GmbH, Hannover, Germany

10 * Corresponding author:

11 Antonia Vlahou, PhD

12 Biomedical Research Foundation, Academy of Athens

13 Soranou Efessiou 4,

14 11527, Athens, Greece

15 Tel: +30 210 6597506

16 Fax: +30 210 6597545

17 E-mail: vlahou@bioacademy.gr

18

19 **TITLE**

20 **Gene expression and coexpression alterations marking evolution of bladder cancer**

21

22 **ABSTRACT**

23 Despite advancements in therapeutics, Bladder Cancer (BLCA) constitutes a major clinical
24 burden, with locally advanced and metastatic cases facing poor survival rates. Aiming at
25 expanding our knowledge of BLCA molecular pathophysiology, we integrated 1,508 publicly
26 available, primary, well-characterized BLCA transcriptomes and investigated alterations in
27 gene expression with stage (T0-Ta-T1-T2-T3-T4). We identified 157 genes and several
28 pathways related prominently with cell cycle, showing a monotonically up- or down-
29 regulated trend with higher disease stage. Genome wide coexpression across stages further
30 revealed intrinsic and microenvironmental gene rewiring programs that shape BLCA
31 evolution. Novel associations between epigenetic factors (CBX7, ZFP2) and BLCA survival
32 were validated in external data. T0 together with advanced stages were heavily infiltrated
33 with immune cells, but of distinct populations. We found AIF1 to be a novel driver of
34 macrophage-based immunosuppression in T4 tumors. Our results suggest a continuum of
35 alterations with increasing malignancy.

36

37 **INTRODUCTION**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 Bladder Cancer (BLCA) accounts for approximately 200,000 annual deaths worldwide and is
39 considered the most expensive cancer to manage[1]. Advances in imaging technologies and
40 drug discovery have improved patient survival and quality of life [1]. However, early-stage
41 incidents [classified as non-muscle invasive (NMI)], still suffer from high rates of disease
42 recurrence, whereas advanced stage [classified as muscle invasive (MI)], and metastatic
43 cancers face poor outcomes [2].

44 Advances in state-of-art molecular profiling technologies have enabled deeper investigations
45 of BLCA, expanding our current understanding of its molecular pathology. According to the
46 dual track model of bladder carcinogenesis [3], papillary-NMI and MI disease develop from
47 different sets of molecular alterations. Studies performing mutational profiling suggest that
48 low grade Ta tumors arise from activating mutations in either FGFR3 or HRAS, which
49 typically result in over-activation of the downstream Akt/PIK3CA/mTOR and RTK/MAPK
50 growth pathways [3]. In contrast, MIBC tumors are thought to develop from dysplastic Tis
51 lesions with non-functional (mutated) TP53 or RB1 tumor suppressive pathways [3].
52 However, it remains unclear how these mutational signatures translate to different gene
53 expression routes. Moreover, the dual track model cannot explain adequately molecular
54 events driving transformation of a papillary-NMI tumor to MI, nor in the case of MIBC,
55 alterations happening before the dissemination to detrusor muscle.

56 In an effort to better understand molecular pathogenesis, various BLCA molecular subtypes
57 have been described [4-15]. Data supporting a continuum of alterations that likely drive
58 bladder carcinogenesis came from MI patients having tumors with a mosaic of both
59 intraepithelial (Tis) and papillary growth patterns, and from MI cancers having traits of
60 papillary-NMI related mutations. Approximately 22% of MI tumors present with activating
61 mutations in PI3KCA and homozygous deletion of the CDKN2A locus, respectively [9], while
62 CDKN2A deletion in MIBC has been observed to occur more frequently in FGFR3 mutated
63 than wild type tumors [16]. Interestingly, comparative mutational analysis between low
64 grade NMI, high grade NMI and MIBC revealed smooth increments or declines in the
65 frequency of mutations in driver genes (FGFR3, KDM6A, TP53, CDKN2A) with increasing
66 malignancy [17]. Additionally, multi-omics analysis of NMIBC identified dysfunctional TP53
67 and RB1 pathways in about ~25% of both Ta and T1 tumors [15].

68 The clinical distinction between NMI and MI diseases and the current understanding of their
69 molecular determinants cannot describe adequately the events driving tumor evolution. On
70 the other hand, molecular subtypes may have important utilities in the diagnosis, prognosis,
71 and decision making, but unfortunately, they represent static entities and their dynamics
72 can only be studied between baseline diagnosis and future recurrences/progressions. In
73 contrast, stage as an ordinal variable reflecting tumor size and depth of invasion, offers a
74 better opportunity for studying the progressive alterations marking tumor initiation, growth,
75 dissemination to detrusor muscle and metastasis.

76 Gene expression studies comparing the stage profiles of BLCA typically involve small sample
77 sizes and are often limited to comparing NMI and MI. To obtain insight into the trajectories
78 of cancer evolution in BLCA, we collected publicly available transcriptomes from bulk tissue
79 samples, and performed a comprehensive stage analysis of 1,508 subjects with primary
80 BLCA, including a novel integrated pathway-to-network analysis. As the disease progresses
81 gradually to higher stages, our results indicate tumor dependencies on concerted alterations
82 of gene expression, with most prominent those involved in cell cycle regulation.

83

84 **METHODS**

85 **Dataset mining**

86 A comprehensive data mining strategy was employed to retrieve studies applying -omics
87 technologies in BLCA. The overall workflow is summarized in **Figure 1**. All genomic urothelial
88 cancer data from cBioportal (including The Cancer Genome Atlas) were downloaded
89 (5/1/2020). Gene Expression Omnibus (GEO) was queried for transcriptomics, additional
90 genomics or protein array datasets using the search terms “bladder cancer” and “urothelial
91 carcinoma”. We also queried ArrayExpress using the special filter “Array express data only”
92 to obtain any additional datasets missing from GEO. All cohort data published or updated
93 between 2010 and 2019, annotated as Homo sapiens, coming from tissue samples with
94 sample size ≥ 10 , were initially retrieved (25/1/2020). All used datasets were published and
95 downloaded anonymized.

96 **Integration of the transcriptomes**

97 Microarray data were summarized to gene level with the package *oligo* [18]. Affymetrix
98 were normalized with the RMA method, while Illumina were filtered based on detection p
99 value < 0.05 , followed by quantile normalization, addition of 1, and transformation to the
100 natural logarithmic scale. Data were annotated using *biomaRt* (v2.42.1) [19] and microarray
101 probes matching to multiple genes were excluded from downstream analysis. The probe
102 with the highest mean across arrays was selected as representative in cases where multiple
103 probes matched to the same gene. Merging of expression matrices was based on the Hugo
104 Gene Symbol using the intersection of genes between studies.

105 **Adjustment for batch effects**

106 To correct for batch effects across different studies in the discovery data, *ComBat* [20],
107 *removeBatchEffect* [21], and *naiveRandRuv* [22] were evaluated. ComBat performed best
108 and was chosen for further use (manuscript in preparation). The quality of corrected data
109 was assessed with *BatchQC* [23] (**Supplementary Figures 1-2**), with boxplots of expression
110 distribution per sample and principal component analysis plot of sample relationships ,with
111 gene expression comparisons of housekeeping to other genes, and with a set of 12 BLCA
112 markers with known regulation across normal-NMI-MI or across normal-low grade- high
113 grade disease (**Supplementary Figure 3**).

114 **Differential expression, monotonicity and functional annotation**

115 To identify genes that form a continuum of changes across BLCA stages, each disease stage
116 was compared against normal samples. Genes significantly affected (Mann-Whitney $p < 0.05$
117 and had also same orientation of change in all comparisons), were extracted ($n = 3,108$
118 genes). We refer to this set as Concordantly Differentially Expressed Genes (CDEGs).
119 Monotonicity for a gene was defined as being a CDEG and additionally having a continuously
120 larger/smaller fold change with increasing stage (fold change, as defined in each disease
121 stage versus normal control). Functional annotation and enrichment were performed using
122 PubMed and the online tool GeneCards (<https://ga.genecards.org/>), respectively.

123 **Monotonicity in pathway activation and analysis for gene coexpression**

124 We utilized CDEGs to infer pathway activation scores and to create stage coexpression
125 networks. Pathway activation scores per sample were calculated with the *ssGSEA-GSVA*
126 method [24], using the Molecular Signature Database libraries of Hallmark, Canonical
127 Pathways (Reactome subset), C3 (GO biological processes subset) and C5 (GTRD subset of
128 transcription factor targets). *Dorothea* (<https://github.com/saezlab/dorothea>) [25] was
129 utilized to assess regulon activity. Activation scores across stages were compared with
130 Mann-Whitney tests, and direction of change was defined based on fold change (= Mean of
131 stage – Mean of T0). Pathways showing a monotonal change in the activation scores with
132 increasing stage were extracted. Monotonicity for a pathway was defined similarly to the
133 previous section, i.e. being significantly different in all stage comparisons to T0, and also
134 having a continuously larger/smaller fold change with increasing stage. Stromal infiltration
135 scores were imputed with the ESTIMATE algorithm [26].

136 Gene-pair coexpression weights (non-negative) were approximated with ensemble learning,
137 using GENIE3 [27] and direction of coexpression (positive/negative) was determined by
138 Spearman's coefficient. Stage specific networks were constructed with igraph using the top
139 5,600 positively correlated gene pair interactions with the highest weights for each of the
140 stages. Networks were analysed with Louvain clustering [28] to identify local modules of
141 significantly higher coexpression relationships (communities) within each stage. The top 5 in
142 size (= number of genes) communities of coexpressed genes per stage were analysed for
143 Gene Ontology Biological Processes [29]. Significance was thresholded at $p < 0.05$ after FDR
144 adjustment according to Benjamini-Hochberg. Hub genes in the monotonal networks were
145 defined based on the betweenness centrality metric.

146 **Statistical analysis**

147 For continuous variables, significance was defined at Mann-Whitney $p < 0.05$, unless stated
148 otherwise. Categorical variables were investigated for significance with the Chi-squared test
149 and were adjusted for multiple hypothesis (CRAN package *RVAideMemoire*). All statistical
150 tests were two sided. Gene Ontology and Reactome pathway enrichment analysis was
151 conducted with functions from the package *ClusterProfiler* that performs a two-sided
152 hypergeometric test. All reported correlation scores correspond to the Spearman's Rank
153 coefficient. Kaplan-Meier analysis and cox proportional hazards regression were performed
154 with the CRAN packages *survminer* and *survival*, and statistical significance was determined
155 with the log-rank method. CIBERSORT analysis was conducted in the web platform
156 <https://cibersort.stanford.edu/>, and only samples with successful deconvolution ($p < 0.05$, n
157 = 350 samples) were further used for the comparisons of relative immune populations
158 among stages. All processing, analyses and visualizations were created in the R programming
159 language (version 4.0.2), using predominantly Bioconductor libraries.

160

Technology	Platform	Dataset ID	T0	Ta	T1	T2	T3	T4	Tis	Study size
Affymetrix	GPL17586	GSE121711	10	3	2	3				18
Affymetrix	GPL17586	GSE93527		79						79
Affymetrix	GPL570	E-MTAB-1940	4	41	41					86
Affymetrix	GPL570	GSE31684		5	10	16	41	18		90
Affymetrix	GPL6244	GSE104922		19	7	10	5	0		41
Affymetrix	GPL6244	GSE128959		13	39				1	53

Affymetrix	GPL6244	GSE83586		13	44	241	1	1	1	301
Illumina	GPL14951	GSE48276			2	6	23	6		37
Illumina	GPL14951	GSE52219				15	7	1		23
Illumina	GPL14951	GSE69795			3	7	27			37
Illumina	GPL6102	GSE13507	67	23	80	31	19	12		232
Illumina	GPL6947	GSE48075		33	34	42	23	8	2	142
		Stage size	81	229	262	371	146	46	4	1139

161 **Table 1:** Stage distribution across the microarray datasets used for the discovery phase.

162

163 RESULTS


164 Cohort description and data quality controls

165 To perform a comprehensive investigation of publicly available omics studies, we collected
166 105 datasets comprising more than 8,000 individuals (**Figure 1**). Minimum inclusion criteria
167 for datasets were defined as having at least stage information per subject. To maintain high
168 integrity, we selected microarray data quantified by commercially available single-color
169 channel vendors (Affymetrix and Illumina). Samples or datasets collected after
170 administration of neoadjuvant chemotherapy (NAC) or not clearly annotated as primary
171 were excluded, generating a final dataset corresponding to 1,508 patients. This included in
172 total 12 microarray studies which were employed as a discovery set (**Table 1**) and in
173 addition, the TCGA 2017 BLCA project based on RNA-seq analysis was used as a validation
174 set (**Figure 1**).

175 The compiled discovery cohort comprised 1,058 primary bladder cancer tumor
176 transcriptomes of treatment-naïve patients without prior cancer history, along with 81
177 adjacent to the cancer bladder samples, a total of 1,139 gene expression profiles (**Table 1**).
178 The ratio of men:woman was 3.5:1, with equal distribution among NMI and MI disease ($p =$
179 0.99) and similar mean ages at baseline diagnosis (68 years, $p = 0.81$). Percentages of normal
180 samples, NMI, and MI in the dataset were 7.1%, 43.5%, and 49.4%, respectively (**Table 1**),
181 with the grade distribution being as follows: 16.5% low grade, 48.8% high grade disease with
182 the remaining samples lacking available grade information. Detailed histological records
183 were missing for 71.5% of the cohort, with the most frequently reported histology among
184 the available records being urothelial/papillary (= 23.3%) with squamous differentiation
185 being the most frequent variant (= 1.3%). Annotations included mutation status for FGFR3,
186 PI3KCA, RAS, RB1 and TP53.

187 Removing batch effects with ComBat was assessed with Relative Log Expression and
188 Principal Component Analysis plots (**Figure 2A**), as well as with comparative analysis of
189 expression levels between housekeeping and non-housekeeping genes (**Figure 2B**), with the
190 algorithm BatchQC (**Supplementary Figures 1 and 2**) [23], or using a set of 12 positive BLCA
191 markers with known regulation across normal-NMI-MI or normal-low-high grade disease
192 (**Supplementary Figure 3**). ComBat successfully eliminated batch effects while maintaining
193 the biological variability (**Figures 2A-C**). BatchQC reports indicated that the variability in the
194 corrected data was generally explained by stage rather than the batch variable
195 (**Supplementary Figure 2**), allowing for an in-depth downstream analysis.

196



197


198 **Figure 1:** Study design and workflow for the integrative analysis of primary BLCA
199 transcriptomes.

200

201 Monotonically changing genes in BLCA regulate growth and cell-cycle progression

202 For initial assessment of the gene expression relations between normal adjacent urothelium
203 (referred to as T0) and cancerous samples, we performed differential expression analysis of
204 T0 versus NMI and T0 versus MI cancers. When compared to T0, a strong positive correlation
205 ($r=0.83$, $p < 2.1 \times 10^{-16}$) was observed between the two sets of log fold change values,
206 suggesting mutual concordance in abundance change and directionality between NMI and
207 MI tumors. To investigate transcriptional changes associated with increasing malignancy,
208 CDEGs were extracted from the comparisons Ta vs T0, T1 vs T0, T2 vs T0, T3 vs T0 and T4 vs
209 T0. A total of 157 genes were identified having a monotonal (i.e. continuously increasing or
210 decreasing in comparison to T0) change in expression across stages, of which 118 were up-
211 and 39 were downregulated with increasing stage (**Table 2**). Functional annotation revealed
212 that for 46 of these genes, experimental evidence on mediating cell cycle progression exists
213 (**Table 2**; **Supplementary Table 1**). Upregulated cell-cycle associated genes ($n = 44$) were not
214 phase specific and included cyclins, DNA polymerases, regulators of the cohesin complex and
215 kinetochore components. The two downregulated cell-cycle associated genes, BTG2 and
216 CDC14B, are both tumor suppressors. The list included 23 genes involved in signal
217 transduction (**Table 2**), 6 of which (ARHGAP11A, AURKA, CDKN3, PBK, PLK1, RRM2), promote
218 cell-cycle progression and were all upregulated with increased stage. The data also indicated
219 an overactivation of the Wnt pathway with increasing disease stage, with its upstream
220 inhibitor APCDD1 being downregulated and its activating ligand WNT2 upregulated
221 (**Supplementary Table 1**). Fourteen of the 157 genes were transcriptional or translational
222 regulators (**Table 2**), including genes with known upregulation in bladder cancer
223 (transcription factors E2F1, DEPDC1 [30, 31]). Based on the monotonal changes with

224 increasing stage, increased androgen receptor activity may be predicted, as both its
 225 translational enhancer BUD31 [32] and its downstream transcription factor ELK1 [33] were
 226 upregulated. Four (HTR2C, LRP8, NENF, NMU) of the 157 genes are involved in
 227 neurotransmission or neuronal development, all upregulated (**Table 2**). Among the 157
 228 genes, 21 genes were of not well described or unknown function (**Supplementary Table 1**),
 229 including the oncogenic factor TRIM65 [34] found upregulated with bladder cancer stage.
 230 Additionally, upregulation was detected for the cisplatin resistance gene CLPTM1L, as well as
 231 for SRD5A1, which catalyzes the conversion of testosterone and progesterone to their 5-
 232 alpha forms [35]. Further functional enrichment using GeneCards for the 157 genes verified
 233 their involvement in cell-cycle pathways, with top hits being related to the regulation of the
 234 Anaphase-promoting (APC) complex (score = 31.53), to PLK1 (score = 24.47) and Aurora B
 235 (score = 20.95) signaling, as well as to TP53 (score = 19.06) and RB1 (score = 17.85) cell cycle
 236 checkpoint control (**Supplementary Table 2**). Using the same tool, analysis for compounds
 237 with potentially therapeutic benefit provided as top hit the DNA alkylating agent
 238 Bendamustine (score = 19.23) (**Supplementary Table 3**) [36]. Univariate cox regression
 239 analysis indicated 29 genes with potentially prognostic impact at $p < 0.01$ (**Supplementary**
 240 **Table 4**).



241
 242 **Figure 2:** ComBat corrected expression data of the discovery cohort and respective
 243 differential gene expression analysis A) Relative Log Expression (right) and Principal
 244 Component Analysis plots (left) showing gene expression levels per sample and sample
 245 relationships, respectively; the different colors denote the different datasets B) dispersion-
 246 to-expression plots illustrating preservation of housekeeping gene properties (higher mean
 247 expression and lower median absolute deviation (MAD) compared to non-housekeeping
 248 genes) in the corrected data, regardless of microarray (top) or RNAseq (bottom) defined
 249 housekeeping genes; C) numbers of differentially expressed genes (DEGs) between disease
 250 stages and normal adjacent urothelium (top), along with respective group sizes (bottom), E)
 251 heatmap of the top (based on fold change) 20 downregulated and top 20 upregulated
 252 monotonically changing genes with increasing disease stage.

253

254

Function	Genes
Cell Cycle	ANLN, ARHGAP11A, AURKA, CDC20, CDCA3, CDCA5, CDCA8, CDK2AP2, CDKN3, CENPA, CENPN, CEP72, KIF23, KIFC1, NEIL3, OIP5, PRC1, PTTG1, RAE1, RUVBL2, SAC3D1, SMC4, FBXO5, CCNA2, CCNB1, CCDC124, CEP55, MKI67, MND1, GINS2, MCM10, MCM4, KIF11, KIF14, NDC80, POLD1, POLE2, PBK, PLK1, RRM2, E2F1, DAXX, E2F7, DTL, BTG2, CDC14B
Signal transduction	ARHGAP11A, AURKA, CDKN3, HTR2C, ITPR3, LRP8, MELK, NENF, NMU, NOX4, PBK, PLK1, PPP1R14C, RRM2, WNT2, AKAP7, APCDD1, IGFBP2, KIT, MTMR9, PPP1R1B, PTCH1, TAPT1
Transcriptional regulation	DAXX, DEPDC1, E2F1, E2F7, ELK1, FOXA3, HOXC6, HOXC9, MED19, TEAD4, AEBP2, CBX7
DNA damage response	CDCA5, EXO1, NDC80, NTHL1, POLD1, POLE2, RAD51AP1, UBE2T
Ubiquitin mediated proteolysis	DTL, FBXW2, PSMB3, PSMC1, TRAF2, DET1
Immunity	ISG15, SPP1, GBP6, IFNAR1, PIGR
Metabolism	CAD, DAGLA, ENO1, IMPDH1, NUDT1, SRD5A1, ADHFE1, ALDH7A1, ASS1, CAT, CHST9, CYP4V2, MGST1
Other roles	ARF5, ARPC5L, BUD31, CLPTM1L, EIF4EBP1, FAM91A1, GP6, PACSIN3, XPO5, CIRBP, GALNT12, RSL1D1, RWDD3, SLC25A27, UST
Homeostasis	ARHGDI1, BOP1, CTSA, GTPBP4, LMNB2, LYAR, MRPL37, NIP7, NXT1, POLR2D, POP7, RBM28, SRPRB, CTSO
Uncertain/Unknown	FAM50A, IGFL2, KIAA2013, MLF2, PAQR4, RECQL4, RP9, SBSN, SLC22A15, SNX8, TRIM65, YIF1A, FYCO1, GARNL3, ICA1L, ITM2C, LONRF1, NHS, NNAT, ZFP2, ZNF181

255 **Table 2:** Classification of the 157 monotonically changing genes with increasing disease BLCA
 256 stage to functional categories. Red and blue colors correspond to upregulation and
 257 downregulation, respectively. More details per gene are provided in **Supplementary Table 1**.


258

259 **The expanded dataset of 3,108 CDEGs links cell-cycle, ECM remodelling and metabolic**
 260 **alterations with increasing disease stage**

261 To increase coverage of the BLCA alterations, we further extracted Concordantly
 262 Differentially Expressed Genes (defined in Methods; CDEGs, n = 3,108) from the comparisons
 263 of cancerous stages to normal adjacent urothelium and investigated the differentially
 264 activated pathways they represent, using ssGSEA. Similar to the analysis of monotonicity, we
 265 sought to identify pathways with monotonically up- or down- regulated activation scores
 266 across T0 and BLCA stages. Results indicated gradually stronger activations of several mitotic
 267 processes, positive regulation of the canonical Wnt pathway, mTORC1 signaling, expression
 268 of MYC targets, degradation of anaphase inhibitors, metabolism of nucleotides, mobility of
 269 formins, and the TNFR2/non-canonical NF-κB pathway (**Figure 3, Supplementary Table 5**).
 270 Conversely, consistently reduced expression versus controls was observed in genes involved
 271 in lipid and fatty acid catabolic processes, in the metabolism of heme, in pathways
 272 promoting muscle cell differentiation and, interestingly, in genes regulating the circadian
 273 clock (**Figure 3**). Regulon activity per sample was estimated and respective scores between

274 cancerous stages and normal tissue were compared. GATA3 and GLI2 were the only regulons
 275 that significantly associated with increasing malignancy with their activity being
 276 downregulated (**Figure 3**).

277



278
 279 Figure 3: Excerpt of the pathways showing a monotonal increase or decline in their
 280 activation scores with higher stage.

281

282 To further investigate genome wide alterations and coexpression patterns associated with
 283 cancer progression, an integrated network-pathway analysis of the different disease stages
 284 was performed, using the 3,108 CDEGs. Out of 9,659,664 weighted gene pair interactions,
 285 the top 5,600 were used as the most representative to build the corresponding networks,
 286 applying Louvain clustering to identify topologically connected communities (modules).
 287 Retrieved gene clusters have high degree of coexpression, and thus changes in their
 288 composition across stages reflect gains/losses in pathway rewiring. We used the Gene
 289 Ontology – Biological Process library to identify molecular processes affected by changes in
 290 coexpression inside the top 5 largest in size (based on number of genes) communities
 291 (**Figure 4, Supplementary Tables 6-11**). The analysis revealed large differences in gene
 292 coexpression between T0 and cancerous samples with 4 out of the 5 largest in size
 293 communities associating clearly with specific biological processes.

294 Three out of the top 5 communities were consistently detected in all BLCA stage networks.
 295 Based on examination of their enriched processes, these were labeled as 1) the cell-cycle
 296 community, 2) the ECM and developmental community 3) the metabolic and translational
 297 community (**Figures 4A, 4B**)

298 When investigating the cell cycle community and specifically the processes of G1/S transition
 299 of mitotic cell cycle, cell-cycle G2/M phase transition, regulation of cell cycle phase
 300 transition, regulation of chromosome organization and nuclear division, most of the
 301 participating genes were found to be coexpressed in all BLCA stages (**Figure 4B**). However,
 302 the gene size of the cell cycle community increased with higher stage (Ta n = 118, T1 n = 148

303 and MIBC n = 168-170), and interestingly, the proportion of the genes with unknown or
304 unclear function (lacking GO annotation) also increased (11.9% for Ta, 29.8% for T4).
305 Among the genes with cell cycle annotation (n=184), 80 genes were coexpressed in all
306 cancerous stages and were also upregulated in malignancy compared to T0, possibly forming
307 the backbone of cell cycle progression in BLCA (Supplementary Table 13). However, only 36
308 of them had a monotonal increase in the expression levels with higher stage (Supplementary
309 Table 13). To detect potential drivers of variation in the cell cycle co-expression profiles of
310 stages, we looked into the betweenness centrality scores of the genes inside each of the
311 stage cell cycle communities (Figure 4C), and found CDCA5 and KIF2C to be hub genes in Ta
312 tumors, FOXM1 and AURKB in T1, CDT1 and SMC4 in T2, CCNB1 and RRM2 in T3 and KIF14 in
313 T4 tumors (Figure 4C).

314


315 The community of ECM and developmental processes was enriched in cell-cell
316 communication and cell-matrix interactions, in responses to microenvironmental stress, as
317 well as in differentiation programs of epithelial, mesenchymal and stem cells (**Figure 5B**).
318 The biological process of extracellular matrix organization included coexpressions of 15-36
319 genes of which COL13A1, FGFR4, FOXF2 and SCUBE1 were coexpressed only in T0 compared
320 to disease stages, whereas 26 genes (including COL6A1/A2, COL16A1, MFAP5, MMP11) were
321 coexpressed in malignancy but not in T0. In line with recent observations [37], we noticed
322 that T0 presented with an active ECM remodeling profile. Sixteen of the ECM associated
323 genes were coexpressed both in T0 and in the NMIBC stages, including genes promoting
324 ECM degradation and tumor cell migration (MMP2, CTSK, PDPN), fibrotic collagens (COL1A2,
325 COL6A3, COL14A1, COL15A1), and pro-angiogenic factors (PDGFRA, RECK). Notably,
326 coexpression in the T0 samples was predicted to be driven by the cancer stem cell marker
327 ALDH1A2 and MFAP4 (**Figure 4C**), while in Ta tumors, by COL16A1 and CLIP3. Since CLIP3
328 interacts with both AKT1 and AKT2 [38], CLIP3 may have an important role in the early
329 AKT/PI3K/mTOR axis of carcinogenesis. For the same process of extracellular matrix
330 organization, compared to Ta, T1 tumors had gains in ADAMTSL2, while compared to T1, T2
331 tumors had gains in MMP11 and LRP1. Similarly compared to T2, T3 tumors had
332 coexpression gains in ITGA10 and in genes of the endocytic pathway (ABL1, CYP1B1)
333 whereas compared to T3, T4 tumors had gains in DDR2 and JAM2.

334 The community of metabolism and translation encompassed mitochondrial, translational
335 and multiple metabolic processes being activated during carcinogenesis, and was more
336 profound in the T1 and more advanced tumors. The processes of cellular respiration,
337 translational initiation, mRNA catabolic process, nonsense mediated decay and protein
338 targeting to ER were consistently enriched in most of BLCA stages. The results highlighted a
339 set of 12 genes commonly co-expressed across stages for these processes, including COX7B,
340 DLD, NDUFS4, UQCRCF1, PAIP2, RPL15, RPL30, RPL7, RPS23, RPS27, RPS27A, RPS4X, with
341 RPL36A and YTHDF3 being T2-specific, COQ10B, EIF4E3, MTIF2, NCPB1 as T3-specific while
342 EIF4E1, ISCU and GSPT2 were T4-specific.

343 Besides the abovementioned consistently detected communities in BLCA, a community
344 enriched in processes of immune cell activation and cytokine secretion, was identified in the
345 T0 and the MIBC stages and involved both innate and adaptive responses, as well as,
346 processes of immune cell adhesion and migration. It was the least variable community with
347 respect to different processes and respective genes coexpressed across the different stages.
348 Strikingly, T0 and the MIBC stages had similar profiles. Out of the 17 genes of the process of

349 T-cell activation that were commonly coexpressed at the MIBC stages, 15 were also
 350 coexpressed in the T0 samples. To further investigate these observations, the transcriptome
 351 data per sample were deconvoluted into relative abundances of immune cell populations
 352 using CIBERSORT, and cell fractions between disease stages were compared. Significant
 353 results were obtained for the following populations: CD8+, activated CD4+, activated NK,
 354 Monocytes, Macrophages M2 and activated Dendritic cells (**Supplementary Figure 4**).
 355 Results indicated differential commitment of immune cells to T0 and BLCA stages. T0 (n = 37)
 356 were significantly more infiltrated with CD8+ (p = 0.046) and monocytes (p = 4.6E-4) than
 357 tumor samples (n = 313), verifying the presence of the immune community in the T0
 358 samples. However, compared to tumor, T0 samples had significantly less abundance of
 359 activated CD4+ cells (p = 5.28E-3), of macrophages (p = 16.8E-5), of activated dendritic cells
 360 (p = 0.0002) and of activated natural killer cells (p = 0.015). Generally, NMIBC had lower
 361 infiltration burden than MIBC, while compared to other BLCA stages, Ta tumors (n = 34)
 362 were significantly more infiltrated with activated dendritic cells (p = 0.024). Abundance of
 363 CD8+, of activated NK cells, and of M2 macrophages increased linearly with higher
 364 malignancy. Interestingly, AIF1 a gene that promotes macrophage survival [39], was found to
 365 be driver of immune coexpression in the T4 tumors.

366



367

368 Figure 4: Biological process analysis of the largest in size coexpressed communities identified
 369 in each BLCA stage, using the 3,108 CDEGs between T0 and cancerous stages. **A)** Coherent
 370 communities identified and characterized across T0 and disease stages. Numbers in
 371 parentheses show the fraction of genes with existing Biological Process annotation with
 372 respect to the total number of genes found to be coexpressed in each of the community **B)**
 373 Barplots of the most significantly enriched biological processes per community depicting

374 number of coexpressed genes for each. C) Hub genes identified across the studied
375 conditions based on the betweenness centrality scores (y axis).

376

377 RNA-seq independent analysis validates presence of communities and prognostic genes

378 In lack of another dataset comprising all the disease stage spectrum of primary BLCA
379 incidents, the observed alterations in the discovery set were investigated for their
380 reproducibility in the TCGA-BLCA publication [9]. Although the validation set is not perfectly
381 suited since it includes only stages T2-T3-T4, we used it due to the RNA-seq technology
382 which offers a good reliability at the validated findings. Differential expression analysis
383 among the available stage comparisons (T3 vs T2 and T4 vs T3) in the TCGA data validated 74
384 of the 157 monotonal genes in the comparison T3vsT2, and none in the comparison T4vsT3
385 (**Supplementary Table 13**). Cox regression analysis of the 157 genes in the TCGA data
386 validated 12 genes having a prognostic value (**Supplementary Table 4**), including IMPDH1,
387 MRPL37, MED19, ENO1, ANLN, GTPBP4, MLF2, higher levels of which associating with worse
388 survival and CBX7, ZFP2, AKAP7, ICA1L, CDC14B higher levels of which associating with
389 better survival probability. To validate as possible the coexpression analysis findings, stage
390 specific coexpression networks were also created using the TCGA data, and were clustered
391 with the Louvain algorithm. GO-Biological process analysis of the communities validated the
392 differential segregation of the cell-cycle, extracellular matrix and immune activation
393 processes to distinct communities (**Supplementary Figure 5**).

394

395 DISCUSSION

396 Early integration of raw BLCA data has been previously performed, in the context of
397 characterizing molecular subtypes [40], or validating results of either scRNA-seq [41] or RNA-
398 seq re-analysis [42]. In this study we performed an early integration meta-analysis of normal
399 looking urothelium and BLCA stages, aiming to identify continuous gene expression
400 alterations with increasing malignancy. To our knowledge, this is the first attempt to
401 associate molecular alterations with clinical classification, by analyzing more than one
402 thousand well-characterized, primary samples. Instead of focusing onto molecular subtypes,
403 we increased power and addressed the disease as a continuum, under the assumption that
404 individual samples reflect different snapshots of the whole process. Our novel design based
405 on the hypothesis of continuous evolution through stages, has been successfully applied
406 here and resulted in novel findings on gene regulation associated with cancer progression.

407 First, we identified a set of 157 genes with a monotonal change in expression across T0 and
408 BLCA stages. Almost half of these genes were components of the cell cycle machinery, or
409 kinases signaling positively for it, or transcription factors responsible for the expression of
410 cell cycle genes. Twelve of the 157 genes had also prognostic value in external RNA-seq data.
411 Of these, apart from ENO1 higher levels of which had been previously linked with worse
412 BLCA outcome [43], all the remaining 11 associations to survival are novel. IMPDH1 plays a
413 role in cancer progression by promoting cell growth, and higher expression levels of this
414 gene have been observed in MIBC compared to normal tissue [44]. Similarly, MED19 a
415 component of the mediator complex that regulates the transcription of RNA-polymerases,
416 was found overexpressed by IHC in human BLCA compared to normal tissues, and its
417 knockdown in the T24 and 5637 bladder cell lines resulted in cell-cycle arrest at the G0/G1

418 checkpoint and also in attenuation of cell growth [45]. The involvement of MRPL37, GTPBP4
419 and MLF2 in BLCA development has not been characterized, but oncogenic properties have
420 been attributed to these genes in other contexts. ANLN and AKAP7 are thought to regulate
421 bladder cell growth and apoptosis in a TP53 independent manner [46]. ICA1L is naturally
422 expressed in sperm cells and its implication in BLCA has not been investigated. The CDC14B
423 gene is located on the 9q chromosome, a region that is often deleted in BLCA. This might
424 also explain its downregulation in malignancy, as observed in the discovery set. CDC14B is
425 believed to dephosphorylate TP53 [47], but the functional consequence on the mitotic or
426 DNA damage repair pathways is not yet well clarified [48]. CBX7 is a component of the
427 chromatin modifier PRC1-complex and is required for the propagation of the
428 transcriptionally repressive state of multiple genes through cell-division during embryonic
429 development [49], including Hox genes [50]. Expectedly, we noticed that HOXC6 and HOXC9
430 were both monotonically upregulated with increasing malignancy (**Supplementary Table 1**).
431 ZFP2 is a probable transcription factor and evidence suggest an epigenetic role as well [51],
432 while recently, high load of mutations in another member of the ZFP family (ZFP36) were
433 associated with upper tract urothelial carcinoma [52].

434 Our analysis highlighted expected landmark pathways, such as mTORC1 pathway [53] and
435 MYC targets [54] which were upregulated, but also novel downregulated pathways such as
436 the circadian clock and the metabolism of heme. These results associate for the first time
437 BLCA progression to the disruption of the circadian homeostasis and to iron metabolism
438 deficiencies, events that are thought to be tumorigenic [55, 56], but their exact mechanism
439 of action is not well understood. We detected an “incomplete” Warburg effect in which the
440 monotonical downregulation (or deactivation) of lipid and fatty acids metabolism, was not
441 accompanied by any upregulation of glycolysis. Additionally, to the GATA3 regulon which is a
442 known driver of luminal biology, we detected a novel progressive downregulation of the
443 GLI2 regulon. GLI proteins are transcription factors of the Sonic hedgehog (Shh) pathway and
444 although GLI2 expression levels positively correlate with more invasive BLCA cell lines, Shh
445 genes do not behave accordingly [57]. Our results validate these observations, as the entire
446 regulon of the GLI2 TF was inactivated with increasing BLCA malignancy, suggesting no
447 potential therapeutic effect in its inhibition.

448 A change in the expression levels of a single gene may not always have a functional
449 consequence, mainly due to the complementary action of other genes of that pathway.
450 Instead, a concerted change in the expression levels of multiple genes is often required for
451 the cell to successfully transit between phenotypes. We investigated this type of changes
452 using a network coexpression analysis followed by intra-stage graph clustering, and were
453 able to detect both intrinsic and microenvironmental gene rewiring programs that shape
454 tumor evolution. These gene programs were found to be organized into distinct biological
455 communities (which were validated in the TCGA 2017 study), and consisted of genes stably
456 coexpressed among all BLCA stages, but also of genes specifically coexpressed (gained or
457 lost) in a particular stage only. We assume that the ECM remodelling relies mostly on this
458 last property of gains and losses in coexpression, since the bladder consists of
459 heterogeneous anatomical tissues with stiff biological barriers (basement membrane,
460 muscle layer), which in turn require specialized cell functions to be dissolved. The immune
461 activation community was present in both T0 and MIBC. Results of the CIBERSORT analysis
462 showed that inside the bladder tumor and with increasing stage, most monocytes
463 preferentially differentiate into macrophages with M2 polarization. This is in line with the
464 recent findings from Chen et al. [41] in which authors analyzed scRNA-seq data of BLCA

465 patients and observed a similar pattern of differentiation for monocytes. As the CIBERSORT
466 algorithm has not been designed to recognize signatures of T-cell exhaustion, CD8+ cells
467 appeared at higher number in T0 samples compared to tumor, however we cannot exclude
468 the existence of biological barriers in the normal adjacent urothelium that forbid CD8+ cells
469 from reaching tumor. T4 samples had the highest percent of M2-macrophages, which could
470 partially explain their immunosuppressive state, and as a novel finding, T4 coexpression in
471 the immune cells was driven by AIF1, a gene that ensures the survival and proliferation of
472 macrophages. We hypothesize that immune evasion in BLCA is likely promoted by M2-
473 macrophages that actively express AIF1, but further work is required to validate these
474 observations.

475 Our study has its limitations, which include the retrospective nature of the analysis, and the
476 usage of batch correction methods to integrate different microarrays. The batch correction
477 method unavoidably eliminates some of the biological variability leading to increased false
478 negative rate; our validation of the applied method via checking expression of known genes,
479 in combination to focusing on positive signals, suggests that sufficient biological variability is
480 maintained. In addition, restrictions in the validation set imposed by lack of samples from all
481 disease stages did not allow validating the observations particularly at the NMIBC. Finally,
482 clinical stage is known to have varying rates of misdiagnosis. However, the high number of
483 samples used in each of the stage categories is expected to balance out to some extent
484 misdiagnosed cases while increasing power of the received results.

485

486 **Data availability**

487 The datasets generated during and/or analysed during the current study are available from
488 the corresponding author on reasonable request.

489

490 **Code availability**

491 All custom R scripts created for analysis and visualizations are available by the first and the
492 corresponding author upon reasonable request.

493

494 **Acknowledgements**

495 MM is supported by the European Union's Horizon 2020 research and innovation
496 programme under the Marie Skłodowska-Curie grant agreement No 898260 (H2020-MSCA-
497 IF-2019, ReDrugBC, Grant agreement ID: 898260).

498

499 **Contributions**

500 HM and AV conceived and designed the investigation, RS, MF, MZ and EM processed and
501 analyzed data, RS and EM wrote software for analysis and visualizations, RS, MF, MZ HM and
502 AV interpreted results, RS wrote the manuscript, MM, MR, HM and AV provided critical
503 revisions.

504

505 **Ethics declarations/ Competing interests**

506 HM is the co-founder and co-owner of Mosaiques Diagnostics, MF, EM, and MM are
507 employed by Mosaiques Diagnostics.

508

509 **References**

510 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
511 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
512 countries. *CA: a cancer journal for clinicians*. 2018;68:394-424.

513 [2] Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into
514 pathogenesis and clinical diversity. *Nature reviews Cancer*. 2015;15:25-41.

515 [3] Czerniak B, Dinney C, McConkey D. Origins of Bladder Cancer. *Annual review of*
516 *pathology*. 2016;11:149-74.

517 [4] Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, et al. Gene
518 expression in the urinary bladder: a common carcinoma in situ gene expression signature
519 exists disregarding histopathological classification. *Cancer research*. 2004;64:4040-8.

520 [5] Sjobahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, et al. A molecular
521 taxonomy for urothelial carcinoma. *Clinical cancer research : an official journal of the*
522 *American Association for Cancer Research*. 2012;18:3377-86.

523 [6] Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic
524 subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.
525 *Proceedings of the National Academy of Sciences of the United States of America*.
526 2014;111:3110-5.

527 [7] Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of
528 distinct basal and luminal subtypes of muscle-invasive bladder cancer with different
529 sensitivities to frontline chemotherapy. *Cancer cell*. 2014;25:152-65.

530 [8] Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C, Chapeaublanc E, et
531 al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers
532 presenting a basal-like phenotype. *Science translational medicine*. 2014;6:244ra91.

533 [9] Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo GW, Cherniack AD, et al.
534 *Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer*. *Cell*.
535 2017;171:540-+.

536 [10] Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi BP, et al. *Comprehensive*
537 *Transcriptional Analysis of Early-Stage Urothelial Carcinoma*. *Cancer cell*. 2016;30:27-42.

538 [11] Hurst CD, Alder O, Platt FM, Droop A, Stead LF, Burns JE, et al. Genomic Subtypes of
539 Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in
540 KDM6A Mutation Frequency. *Cancer cell*. 2017;32:701-15 e7.

541 [12] Sjobahl G, Eriksson P, Liedberg F, Hoglund M. Molecular classification of urothelial
542 carcinoma: global mRNA classification versus tumour-cell phenotype classification. *The*
543 *Journal of pathology*. 2017;242:113-25.

544 [13] Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K, et al. Prognostic Power of a Tumor
545 Differentiation Gene Signature for Bladder Urothelial Carcinomas. *Journal of the National*
546 *Cancer Institute*. 2018;110:448-59.

547 [14] Kamoun A, de Reynies A, Allory Y, Sjobahl G, Robertson AG, Seiler R, et al. A Consensus
548 Molecular Classification of Muscle-invasive Bladder Cancer. *European urology*. 2020;77:420-
549 33.

550 [15] Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtroder K, et al.
551 An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-
552 invasive bladder cancer. *Nature communications*. 2021;12:2301.

- 553 [16] Rebouissou S, Herault A, Letouze E, Neuzillet Y, Laplanche A, Ofualuka K, et al. CDKN2A
554 homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial
555 bladder carcinoma. *Journal of Pathology*. 2012;227:315-24.
- 556 [17] Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, et al. Mutational
557 Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. *Clinical Cancer*
558 *Research*. 2019;25:2458-70.
- 559 [18] Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing.
560 *Bioinformatics*. 2010;26:2363-7.
- 561 [19] Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of
562 genomic datasets with the R/Bioconductor package biomaRt. *Nature protocols*.
563 2009;4:1184-91.
- 564 [20] Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
565 using empirical Bayes methods. *Biostatistics*. 2007;8:118-27.
- 566 [21] Smyth GK, Speed T. Normalization of cDNA microarray data. *Methods*. 2003;31:265-73.
- 567 [22] Jacob L, Gagnon-Bartsch JA, Speed TP. Correcting gene expression data when neither
568 the unwanted variation nor the factor of interest are observed. *Biostatistics*. 2016;17:16-28.
- 569 [23] Manimaran S, Selby HM, Okrah K, Ruberman C, Leek JT, Quackenbush J, et al. BatchQC:
570 interactive software for evaluating sample and batch effects in genomic data.
571 *Bioinformatics*. 2016;32:3836-8.
- 572 [24] Hanzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray
573 and RNA-Seq data. *Bmc Bioinformatics*. 2013;14.
- 574 [25] Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and
575 integration of resources for the estimation of human transcription factor activities. *Genome*
576 *Res*. 2019;29:1363-75.
- 577 [26] Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al.
578 Inferring tumour purity and stromal and immune cell admixture from expression data.
579 *Nature communications*. 2013;4.
- 580 [27] Huynh-Thu VA, Irrthum A, Wehenkel L, Geurts P. Inferring Regulatory Networks from
581 Expression Data Using Tree-Based Methods. *PloS one*. 2010;5.
- 582 [28] Blondel VD, Guillaume JL, Lambiotte R, Lefebvre E. Fast unfolding of communities in
583 large networks. *J Stat Mech-Theory E*. 2008.
- 584 [29] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological
585 themes among gene clusters. *OmicS : a journal of integrative biology*. 2012;16:284-7.
- 586 [30] Lee SR, Roh YG, Kim SK, Lee JS, Seol SY, Lee HH, et al. Activation of EZH2 and SUZ12
587 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of
588 Bladder Cancer. *Clinical cancer research : an official journal of the American Association for*
589 *Cancer Research*. 2015;21:5391-403.
- 590 [31] Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of
591 upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. *Oncogene*.
592 2007;26:6448-55.
- 593 [32] Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, et al. Identification of a new androgen
594 receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated
595 AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.
596 *Molecular oncology*. 2014;8:1575-87.
- 597 [33] Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, et al. ELK1 is up-regulated
598 by androgen in bladder cancer cells and promotes tumor progression. *Oncotarget*.
599 2015;6:29860-76.
- 600 [34] Wei WS, Chen X, Guo LY, Li XD, Deng MH, Yuan GJ, et al. TRIM65 supports bladder
601 urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and
602 degradation. *Cancer letters*. 2018;435:10-22.

- 603 [35] Pham H, Ziboh VA. 5 alpha-reductase-catalyzed conversion of testosterone to
604 dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-
605 lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids. *The Journal of*
606 *steroid biochemistry and molecular biology.* 2002;82:393-400.
- 607 [36] Leoni LM, Hartley JA. Mechanism of action: the unique pattern of bendamustine-
608 induced cytotoxicity. *Seminars in hematology.* 2011;48 Suppl 1:S12-23.
- 609 [37] Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S, et al. Bladder Tumor Subtype
610 Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM
611 Remodeling. *Cancer research.* 2021;81:1552-66.
- 612 [38] Ding J, Du K. ClipR-59 interacts with Akt and regulates Akt cellular
613 compartmentalization. *Molecular and cellular biology.* 2009;29:1459-71.
- 614 [39] Egana-Gorrondo L, Chinnasamy P, Casimiro I, Almonte VM, Parikh D, Oliveira-Paula GH, et
615 al. Allograft inflammatory factor-1 supports macrophage survival and efferocytosis and limits
616 necrosis in atherosclerotic plaques. *Atherosclerosis.* 2019;289:184-94.
- 617 [40] Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP. Molecular Subtypes of Urothelial
618 Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. *European urology.*
619 2019;75:423-32.
- 620 [41] Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, et al. Single-cell RNA sequencing highlights
621 the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma.
622 *Nature communications.* 2020;11:5077.
- 623 [42] Chen X, Chen H, He D, Cheng Y, Zhu Y, Xiao M, et al. Analysis of Tumor
624 Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint
625 Inhibitor Therapy. *Frontiers in immunology.* 2021;12:672158.
- 626 [43] Ji M, Wang Z, Chen J, Gu L, Chen M, Ding Y, et al. Up-regulated ENO1 promotes the
627 bladder cancer cell growth and proliferation via regulating beta-catenin. *Bioscience reports.*
628 2019;39.
- 629 [44] Lee SJ, Lee EJ, Kim SK, Jeong P, Cho YH, Yun SJ, et al. Identification of pro-inflammatory
630 cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.
631 *PloS one.* 2012;7:e40267.
- 632 [45] Zhang H, Jiang H, Wang W, Gong J, Zhang L, Chen Z, et al. Expression of Med19 in
633 bladder cancer tissues and its role on bladder cancer cell growth. *Urologic oncology.*
634 2012;30:920-7.
- 635 [46] da Silva GN, Evangelista AF, Magalhaes DA, Macedo C, Bufalo MC, Sakamoto-Hojo ET, et
636 al. Expression of genes related to apoptosis, cell cycle and signaling pathways are
637 independent of TP53 status in urinary bladder cancer cells. *Molecular biology reports.*
638 2011;38:4159-70.
- 639 [47] Li L, Ljungman M, Dixon JE. The human Cdc14 phosphatases interact with and
640 dephosphorylate the tumor suppressor protein p53. *The Journal of biological chemistry.*
641 2000;275:2410-4.
- 642 [48] Dietachmayr M, Rathakrishnan A, Karpiuk O, von Zweyendorf F, Engleitner T, Fernandez-
643 Saiz V, et al. Antagonistic activities of CDC14B and CDK1 on USP9X regulate WT1-dependent
644 mitotic transcription and survival. *Nature communications.* 2020;11:1268.
- 645 [49] Moussa HF, Bsteh D, Yelagandula R, Pribitzer C, Stecher K, Bartalska K, et al. Canonical
646 PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing.
647 *Nature communications.* 2019;10:1931.
- 648 [50] Grossniklaus U, Paro R. Transcriptional silencing by polycomb-group proteins. *Cold*
649 *Spring Harbor perspectives in biology.* 2014;6:a019331.
- 650 [51] Sobocinska J, Molenda S, Machnik M, Oleksiewicz U. KRAB-ZFP Transcriptional
651 Regulators Acting as Oncogenes and Tumor Suppressors: An Overview. *International journal*
652 *of molecular sciences.* 2021;22.

- 653 [52] Su X, Lu X, Bazai SK, Comperat E, Mouawad R, Yao H, et al. Comprehensive integrative
654 profiling of upper tract urothelial carcinomas. *Genome biology*. 2021;22:7.
- 655 [53] Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the
656 PI3K/Akt/mTOR pathway. *Lab Invest*. 2010;90:1406-14.
- 657 [54] Mahe M, Dufour F, Neyret-Kahn H, Moreno-Vega A, Beraud C, Shi M, et al. An
658 FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in
659 bladder cancers. *EMBO molecular medicine*. 2018;10.
- 660 [55] Fu L, Kettner NM. The circadian clock in cancer development and therapy. *Progress in
661 molecular biology and translational science*. 2013;119:221-82.
- 662 [56] Chen Y, Fan Z, Yang Y, Gu C. Iron metabolism and its contribution to cancer (Review).
663 *International journal of oncology*. 2019;54:1143-54.
- 664 [57] Mechlin CW, Tanner MJ, Chen M, Buttyan R, Levin RM, Mian BM. Gli2 expression and
665 human bladder transitional carcinoma cell invasiveness. *The Journal of urology*.
666 2010;184:344-51.

667

668